Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Multiple Myeloma
Study: Menarini’s CellSearch technology effective in measuring and monitoring CTC levels in multiple myeloma
While biopsy is the conventional method of CTC characterization, Menarini’s minimally invasive Cellsearch platform was found to be an effective tool in the monitoring and management of CTC in patients in the early stages of the disease.
December 15, 2022
Scopio digital platform enables bone marrow aspirate imaging
Bone marrow aspirates are normally conducted manually, using microscopic analysis of cells to diagnose cancers such as leukemia and multiple myeloma.
September 7, 2022
Study recommends screening for adults at risk of multiple myeloma
"We know that in cancers such as breast cancer and lung cancer screening, early detection and early intervention can make a difference in patient survival," senior author Dr. Irene Ghobrial of the Dana-Farber Cancer Institute in Boston said in a statement. "We have shown for the first time that with highly sensitive screening techniques, it may eventually be possible to make a difference in the survival of people at elevated risk for multiple myeloma."
December 10, 2021
Menarini introduces multiple myeloma assay
The new assay captures and enumerates CMMCs from peripheral blood. It has the potential to reduce bone marrow biopsies with a noninvasive method to monitor multiple myeloma evolution and study disease biology.
March 31, 2021
AbbVie gets FDA nod for new use of Venclexta
The approval supports use of Venclexta with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed AML in patients ages 75 or older or those who have comorbidities that preclude the use of intensive induction chemotherapy. AbbVie tested the drug's efficacy using next-generation sequencing in similar trials for multiple myeloma.
October 18, 2020
Sebia teams with Sanofi on myeloma response test
Isatuximab is an anti-CD38 monoclonal antibody. According to the companies, the new Hydrashift 2/4 test will counter potential interference by isatuximab in immunofixation electrophoresis (IFE) tests, which assess complete response to treatment in patients with multiple myeloma. The test kit will be designed for use with Sebia's Hydragel IFE test and will be specifically for isatuximab.
January 6, 2020
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
AbbVie to deploy Adaptive's clonoSeq test in myeloma trials
Venclexta is currently approved by the U.S. Food and Drug Administration (FDA) for use in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, and in older patients with newly diagnosed acute myeloid leukemia who can't tolerate intensive chemotherapy. It is being tested for a number of additional indications, including multiple myeloma.
December 8, 2019
Page 1 of 1